Dr. Phuong Khanh (P.K.) Morrow brings to Takeda Pharmaceuticals more than a decade of leadership experience in global drug development. Prior to joining Takeda Pharmaceuticals, she served as the Chief Medical Officer at CRISPR Therapeutics, where, in partnership with Vertex Pharmaceuticals, she helped lead the development of exa-cel, the first CRISPR gene-edited therapy to be approved for the treatment of severe sickle disease and transfusion-dependent beta thalassemia. Prior to her tenure at CRISPR Therapeutics, Dr. Morrow served in various positions of ascending levels at Amgen. During her career, Dr. Morrow has demonstrated an outstanding track record in bringing novel medicines through all phases of clinical development and global regulatory approval. Specializing in the therapeutic areas of oncology and hematology, she has been responsible for end-to-end development of numerous drug candidates and for the implementation of strategic partnerships with academic institutions, key opinion leaders and biopharmaceutical co-collaborators to facilitate the successful execution of clinical trials.